Gebe Hastalarda İlaç Kullanımı
Özet
Gebelik dönemindeki yoğun bakım yatışları, tüm gebeliklerin yaklaşık %2'sini etkilemekte ve genellikle doğum sonrası kanama veya preeklampsi gibi nedenlerle son aylarda gerçekleşmektedir. Bu kritik süreçte ilaç yönetimi; gebeliğe bağlı anatomik ve fizyolojik değişimlerin farmakokinetiği (absorpsiyon, dağılım, metabolizasyon, eliminasyon) doğrudan etkilemesi nedeniyle multidisipliner bir yaklaşım gerektirir. Tedavide yaygın kullanılan ilaçlar, fetüse yönelik risklerine göre FDA'in A, B, C, D ve X kategorileri kapsamında sınıflandırılmaktadır. Gebelikte artan plazma hacmi, azalan protein bağlama ve yükselen glomerüler filtrasyon hızı (GFR) gibi faktörler nedeniyle standart yetişkin dozlarının kullanılması yetersiz veya toksik sonuçlar doğurabilir; bu nedenle doz ayarlamaları kritik öneme sahiptir. Yoğun bakımda sıklıkla tercih edilen stres ülseri profilaksisi ilaçları, heparin, sedatifler ve antibiyotikler gibi ajanların plasental geçişleri ve fetal etkileri özenle analiz edilmelidir. Çoğu ilacın gebe popülasyonundaki güvenlik profili etik kısıtlamalar nedeniyle tam olarak bilinmediğinden, jinekolog, yoğun bakım ekibi ve klinik eczacının iş birliği içinde çalışması tedavi başarısını artırmakta ve olası riskleri en aza indirmektedir.
Intensive care admissions during pregnancy affect approximately 2% of all pregnancies and mostly occur in the final months due to reasons like postpartum hemorrhage or preeclampsia. Drug management in this critical period requires a multidisciplinary approach, as anatomical and physiological changes associated with pregnancy directly alter pharmacokinetics (absorption, distribution, metabolism, elimination). Commonly used drugs in therapy are classified under the FDA's A, B, C, D, and X categories based on their fetal risks. Factors such as increased plasma volume, decreased protein binding, and elevated glomerular filtration rate (GFR) during pregnancy mean that utilizing standard adult doses can lead to insufficient or toxic outcomes; therefore, dosage adjustments are of critical importance. The placental transfer and fetal effects of agents frequently preferred in intensive care, such as stress ulcer prophylaxis drugs, heparin, sedatives, and antibiotics, must be carefully analyzed. Since the safety profile of most drugs in the pregnant population is not fully known due to ethical constraints, the collaborative work of a multidisciplinary team including gynecologists, the intensive care team, and clinical pharmacists enhances therapeutic success and minimizes potential risks.
Referanslar
Pollock W, Rose L, Dennis CL. Pregnant and postpartum admissions to the intensive care unit: a systematic review. Intensive Care Med. 2010;36(9),1465-1474.
Zieleskiewicz L, Chantry A, Duclos G et al. Intensive care and pregnancy: Epidemiology and general principles of management of obstetrics ICU patients during pregnancy. Anaesth Crit Care Pain Med. 2016;35 Suppl 1:S51-S7.
Law R, Bozzo P, Koren G, et al. FDA pregnancy risk categories and the CPS: do they help or are they a hindrance?. Can Fam Physician. 2010;56(3):239-241.
Feghali M, Venkataramanan R, Caritis S. Pharmacokinetics of drugs in pregnancy. Semin Perinatol. 2015;39(7),512-519.
Dawes M, Chowienczyk PJ. Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2001;15(6),819-826.
Hebert MF, Easterling TR, Kirby B et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. Clin Pharmacol Ther. 2008;84(2),248-253.
Gerson LB. Treatment of gastroesophageal reflux disease during pregnancy. Gastroenterol Hepatol (NY). 2012;8(11),763-764.
Pasternak B, Hviid A. Use of proton-pump inhibitors in early pregnancy and the risk of birth defects. N Engl J Med. 2010;363(22),2114-2123.
James AH. Venous Thromboembolism in Pregnancy. Arterioscl Throm Vas. 2009;29(3),326-331.
Babb M, Koren G, Einarson A. Treating pain during pregnancy. Can Fam Physician. 2010;56(1),25-27.
Pinheiro EA, Wisner KL, Clark CT. Quetiapine Dose Adjustments in Pregnant and Postpartum Women With Bipolar Disorder. J Clin Psychopharmacol. 2018;38(1),89-91.
Kitsiripant C, Kamata K, Kanamori R et al. Postoperative management with dexmedetomidine in a pregnant patient who underwent AVM nidus removal: a case report. JA Clin Rep. 2017;3(1),17. https://dx.doi.org/10.1186%2Fs40981-017-0085-6
Neuman G, Koren G. Safety of procedural sedation in pregnancy. J Obstet Gynaecol Can. 2013;35(2),168-173.
Hall J. B. Yoğun Bakım El Kitabı. D. Özcengiz (Ed), Yoğun Bakım Ünitesinde Analjezi ve Sedasyon. Adana Nobel Kitabevi. 2011: 10-11.
NİMBEXTM 10 mg /5 ml Enjeksiyonluk Çözelti, Kısa Ürün Bilgisi.
VECRON 10mg İ.V. Enjeksiyonluk Çözelti Hazırlamak için Liyofilize Toz ve Çözücü, Kısa Ürün Bilgisi.
PAVULON 4 mg/2 ml IV ampul, Kısa Ürün Bilgisi.
https://www.uptodate.com/contents/flecainide-drug information search flecainide source panel search result selected Title 1 100 usage type panel kp tab drug general display rank 1 F13386419.
Joglar JA, Page RL. Treatment of cardiac arrhythmias during pregnancy: safety considerations. Drug Saf. 1999;20(1),85-94.
CEFAKS 500 mg I.M. Enjektabl Toz İçeren Flakon, Kısa Ürün Bilgisi.
Banos JE, Cruz, N., Farre, M. Use of antibiotics in pregnant patients in the intensive care unit. Rello J, Kollef M, Diaz E, Rodriguez A (Eds), Infectious diseases in critical care. Springer. 2007: 168-181.
Andersen JT, Petersen M, Jimenez-Solem E et al. Clarithromycin in early pregnancy and the risk of miscarriage and malformation: a register based nationwide cohort study. PLoS One. 2013;8(1),e53327.
https://www.health.qld.gov.au/__data/assets/pdf_file/0030/444558/tb-guideline-pregnancy.pdf
Khilnani GC, Zirpe K, Hadda V et al., Guidelines for antibiotic prescription in intensive care unit. Indian J Crit Care Med. 2019;23(Suppl 1),S1-S63.
https://www.uptodate.com/contents/search
Van Kampenhout E, Bolhuis MS, Alffenaar JC et al. Pharmacokinetics of moxifloxacin and linezolid during and after pregnancy in a patient with multidrug-resistant tuberculosis. Eur Respir J. 2017;49(3),1601724.
Denti P, Martinson N, Cohn S et al. Population pharmacokinetics of rifampin in pregnant women with tuberculosis and HIV coinfection in Soweto, South Africa. Antimicrob Agents Ch. 2016;60(3),1234-1241.
